Last reviewed · How we verify
Anastrozole or Letrozole or Exemestane
These aromatase inhibitors block the enzyme aromatase to reduce estrogen production in postmenopausal women with hormone receptor-positive breast cancer.
These aromatase inhibitors block the enzyme aromatase to reduce estrogen production in postmenopausal women with hormone receptor-positive breast cancer. Used for Hormone receptor-positive breast cancer, adjuvant treatment in postmenopausal women, Hormone receptor-positive metastatic breast cancer in postmenopausal women.
At a glance
| Generic name | Anastrozole or Letrozole or Exemestane |
|---|---|
| Also known as | Clinical Practice, Experimental arm |
| Sponsor | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy |
| Drug class | Aromatase inhibitor |
| Target | Aromatase (CYP19A1) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Aromatase inhibitors (anastrozole, letrozole, and exemestane) work by inhibiting the aromatase enzyme, which converts androgens to estrogen in postmenopausal women. By reducing circulating estrogen levels, these drugs suppress the growth of estrogen-dependent breast cancer cells. They are used as adjuvant therapy or for metastatic disease in hormone receptor-positive breast cancer.
Approved indications
- Hormone receptor-positive breast cancer, adjuvant treatment in postmenopausal women
- Hormone receptor-positive metastatic breast cancer in postmenopausal women
Common side effects
- Hot flashes
- Arthralgia/joint pain
- Fatigue
- Headache
- Osteoporosis/bone loss
- Vaginal dryness
- Nausea
Key clinical trials
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (PHASE3)
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial (PHASE3)
- Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (PHASE3)
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PHASE1)
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (PHASE3)
- Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (PHASE2)
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) (PHASE3)
- A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: